GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity

References

• Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
   Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa12-15134
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6; PMID:21984804; http://dx.doi.org/10.1182/blood-2011-05-354449
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19:620-6; PMID:21157437; http://dx.doi.org/10.1038/mt.2010.272
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183:5563-74; PMID:19843940; http://dx.doi.org/10.4049/jimmunol.0900447
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 2009; 15:169-80; PMID:19118044; http://dx.doi.org/10.1158/1078-0432.CCR-08-1638
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK et al. EGFRvIII mCAR-modified T-Cell therapy cures mice with established intracerebral glioma and generates host immunity against Tumor-Antigen loss. Clin Cancer Res 2014; 20:972-84; PMID:24352643; http://dx.doi.org/10.1158/1078-0432.CCR-13-0709
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-86; PMID:20631379; http://dx.doi.org/10.1182/blood-2010-01-265041
   PubMed Web of Science ®Google Scholar
• Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210:1125-35; PMID:23712432; http://dx.doi.org/10.1084/jem.20130110
   PubMed Web of Science ®Google Scholar
• Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005; 5:701-13; PMID:16149873; http://dx.doi.org/10.1586/14737159.5.5.701
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A 1996; 93:14827-32; PMID:8962140; http://dx.doi.org/10.1073/pnas.93.25.14827
   PubMed Web of Science ®Google Scholar
• Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther 2007; 82:734-9; PMID:17898707; http://dx.doi.org/10.1038/sj.clpt.6100369
   PubMed Web of Science ®Google Scholar
• Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005; 36:170-9; PMID:15754294; http://dx.doi.org/10.1016/j.humpath.2004.12.002
   PubMed Web of Science ®Google Scholar
• Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res 2006; 12:4545-52; PMID:16899600; http://dx.doi.org/10.1158/1078-0432.CCR-06-0865
   PubMed Web of Science ®Google Scholar
• Charney AN, Egnor RW, Alexander-Chacko JT, Zaharia V, Mann EA, Giannella RA. Effect of E. coli heat-stable enterotoxin on colonic transport in guanylyl cyclase C receptor-deficient mice. Am J Physiol Gastrointest Liver Physiol 2001; 280:G216-21; PMID:11208543
   PubMed Web of Science ®Google Scholar
• Kuhn M, Adermann K, Jahne J, Forssmann WG, Rechkemmer G. Segmental differences in the effects of guanylin and Escherichia coli heat-stable enterotoxin on Cl− secretion in human gut. J Physiol 1994; 479(Pt 3):433-40; PMID:7837099; http://dx.doi.org/10.1113/jphysiol.1994.sp02-0307
   PubMed Web of Science ®Google Scholar
• Guarino A, Cohen MB, Overmann G, Thompson MR, Giannella RA. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig Dis Sci 1987; 32:1017-26; PMID:3304888; http://dx.doi.org/10.1007/BF01297193
   PubMed Web of Science ®Google Scholar
• Hodson CA, Ambrogi IG, Scott RO, Mohler PJ, Milgram SL. Polarized apical sorting of guanylyl cyclase C is specified by a cytosolic signal. Traffic 2006; 7:456-64; PMID:16536743; http://dx.doi.org/10.1111/j.1600-0854.2006.00398.x
   PubMed Web of Science ®Google Scholar
• Wolfe HR, Mendizabal M, Lleong E, Cuthbertson A, Desai V, Pullan S, Fujii DK, Morrison M, Pither R, Waldman SA. In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. J Nucl Med 2002; 43:392-9; PMID:11884500
   PubMed Web of Science ®Google Scholar
• Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung JA, Wyant T, Fasanmade A, Messersmith WA, Rodon J. Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res 2016; PMID:27178743; http://dx.doi.org/10.1158/1078-0432.ccr-15-2474
   PubMed Web of Science ®Google Scholar
• Marszalowicz GP, Snook AE, Magee MS, Merlino D, Bertman-Booty LD, Waldman SA. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. OncoTarget 2014; 5:9460-71; PMID:25294806; http://dx.doi.org/10.18632/oncotarget.2455
   PubMed Web of Science ®Google Scholar
• Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol 2014; 44:1956-66; PMID:24771148; http://dx.doi.org/10.1002/eji.201444539
   PubMed Web of Science ®Google Scholar
• Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC et al. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res 2009; 69:3537-44; PMID:19351847; http://dx.doi.org/10.1158/0008-5472.CAN-08-3386
   PubMed Web of Science ®Google Scholar
• Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL et al. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst 2008; 100:950-61; PMID:18577748; http://dx.doi.org/10.1093/jnci/djn178
   PubMedGoogle Scholar
• Robinson E, Bartal A, Mekori T. Results of postoperative treatment of colorectal cancer by radiotherapy, chemotherapy and immunotherapy. Recent Results Cancer Res 1980; 75:80-7; PMID:7232842; http://dx.doi.org/10.1007/978-3-642-81491-4_13
   PubMedGoogle Scholar
• Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA, Fiorentini S, Peroni L, Fallacara F, Dima F, Balsari A et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997; 27:71-6; PMID:9000587; http://dx.doi.org/10.1002/(SICI)1097-0320(19970101)27:1%3c71::AID-CYT-O9%3e3.0.CO;2-O
   PubMedGoogle Scholar
• Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225:1487-9; PMID:6332379; http://dx.doi.org/10.1126/science.6332379
   PubMed Web of Science ®Google Scholar
• Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996; 56:2832-6; PMID:8665522
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013; 31:999-1008; PMID:24142051; http://dx.doi.org/10.1038/nbt.2725
   PubMed Web of Science ®Google Scholar
• Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013; 20:1029-32; PMID:23804078; http://dx.doi.org/10.1038/gt.2013.34
   PubMed Web of Science ®Google Scholar
• Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 2005; 11:8549-56; PMID:16361536; http://dx.doi.org/10.1158/1078-0432.CCR-05-1624
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA, Abken H. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012; 143:1095-107 e2; PMID:22750462; http://dx.doi.org/10.1053/j.gastro.2012.06.037
   PubMed Web of Science ®Google Scholar
• Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TN, Haanen JB, van der Burg SH, Melief CJ, Offringa R. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008; 68:8446-55; PMID:18922918; http://dx.doi.org/10.1158/0008-5472.CAN-08-1864
   PubMed Web of Science ®Google Scholar
• Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest 2011; 121:3578-88; PMID:21865642; http://dx.doi.org/10.1172/JCI57925
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004; 173:7647-53; PMID:15585893; http://dx.doi.org/10.4049/jimmunol.173.12.7647
   PubMed Web of Science ®Google Scholar
• Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-Cells for cancer therapy. J Natl Cancer Inst 2016; 108; PMID:26819347; https://dx.doi.org/10.1093/jnci/djv439
   PubMedGoogle Scholar
• Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 1985; 317:359-61; PMID:3876513; http://dx.doi.org/10.1038/317359a0
   PubMed Web of Science ®Google Scholar
• Bar F, Sina C, Hundorfean G, Pagel R, Lehnert H, Fellermann K, Büning J. Inflammatory bowel diseases influence major histocompatibility complex class I (MHC I) and II compartments in intestinal epithelial cells. Clin Exp Immunol 2013; 172:280-9; PMID:23574324; http://dx.doi.org/10.1111/cei.12047
   PubMed Web of Science ®Google Scholar
• Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 2003; 197:985-95; PMID:12695490; http://dx.doi.org/10.1084/jem.20021804
   PubMed Web of Science ®Google Scholar
• Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther 2014; 22:1029-38; PMID:24572294; http://dx.doi.org/10.1038/mt.2014.28
   PubMed Web of Science ®Google Scholar
• Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, Trapani JA, Neeson P, Smyth MJ, Kershaw MH et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 2010; 70:9591-8; PMID:21098715; http://dx.doi.org/10.1158/0008-5472.CAN-10-2884
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010; 184:1885-96; PMID:20089697; http://dx.doi.org/10.4049/jimmunol.0901440
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010; 120:3953-68; PMID:20978347; http://dx.doi.org/10.1172/JCI43490
   PubMed Web of Science ®Google Scholar
• Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013; 20(11):1029-32; PMID:23804078; https://dx.doi.org/10.1038/gt.2013.34
   PubMed Web of Science ®Google Scholar
• Xu XJ, Song DG, Poussin M, Ye Q, Sharma P, Rodriguez-Garcia A, Tang YM, Powell DJ. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. Oncotarget 2016; https://dx.doi.org/10.18632/oncotarget.10510
   Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Peper JK, Schuster H, Loffler MW, Schmid-Horch B, Rammensee HG, Stevanovic S. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods 2014; 405:192-8; PMID:24486140; http://dx.doi.org/10.1016/j.jim.2014.01.012
   PubMed Web of Science ®Google Scholar